TY - JOUR
T1 - COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients
T2 - A Cross Sectional Study in Iran
AU - Nabavi, Seyed Massood
AU - Mehrabani, Mehrnoosh
AU - Ghalichi, Leila
AU - Nahayati, Mohammad Ali
AU - Ghaffari, Mehran
AU - Ashtari, Fereshteh
AU - Mohammadianinejad, Seyed Ehsan
AU - Karimi, Shahedeh
AU - Faghani, Leila
AU - Yazdanbakhsh, Sepideh
AU - Najafian, Abbas
AU - Shahpasand, Koorosh
AU - Vosough, Massoud
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Multiple sclerosis (MS) is a chronic, predominantly immune-mediated degenerative disease of the central nervous system. Due to prolonged use of immunomodulatory and immunosuppressive medications, vaccine hesitancy could be common among MS patients. Our main aim in the current study was to evaluate the willingness and acceptability of COVID-19 vaccination in patients with MS. In our multicenter cross-sectional questionnaire-based clinical study, 892 patients completed the questionnaire between May to June 2021. The questionnaire consisted of demographic data, MS disease-related factors, history of COVID-19 infection/vaccination, and any existing comorbidities. Statistical analysis was performed using SPSS software version 19. Overall, 68% of the participants expressed willingness to be vaccinated. Major causes of vaccine refusal in our patients were the fear of reducing the efficacy of disease modifying drugs (DMDs) upon vaccination as well as distrusting the vaccines and overestimation bias in the power of their innate immunity and potential COVID-19 resistance. Some demographic factors affected vaccination enthusiasm in our study. Our findings did not show significant correlation between the age and comorbidity and vaccine willingness. Only one-third of our patients received their vaccine information from healthcare providers. The majority of them received these data from official broadcasting channels and social media. However, despite several concerns, the willingness of COVD-19 vaccination in the Iranian MS patients is remarkable.
AB - Multiple sclerosis (MS) is a chronic, predominantly immune-mediated degenerative disease of the central nervous system. Due to prolonged use of immunomodulatory and immunosuppressive medications, vaccine hesitancy could be common among MS patients. Our main aim in the current study was to evaluate the willingness and acceptability of COVID-19 vaccination in patients with MS. In our multicenter cross-sectional questionnaire-based clinical study, 892 patients completed the questionnaire between May to June 2021. The questionnaire consisted of demographic data, MS disease-related factors, history of COVID-19 infection/vaccination, and any existing comorbidities. Statistical analysis was performed using SPSS software version 19. Overall, 68% of the participants expressed willingness to be vaccinated. Major causes of vaccine refusal in our patients were the fear of reducing the efficacy of disease modifying drugs (DMDs) upon vaccination as well as distrusting the vaccines and overestimation bias in the power of their innate immunity and potential COVID-19 resistance. Some demographic factors affected vaccination enthusiasm in our study. Our findings did not show significant correlation between the age and comorbidity and vaccine willingness. Only one-third of our patients received their vaccine information from healthcare providers. The majority of them received these data from official broadcasting channels and social media. However, despite several concerns, the willingness of COVD-19 vaccination in the Iranian MS patients is remarkable.
KW - COVID-19 vaccination
KW - Multiple sclerosis
KW - Vaccine acceptability
KW - Vaccine hesitancy
KW - Vaccine willingness
UR - https://www.scopus.com/pages/publications/85123247761
UR - https://www.scopus.com/inward/citedby.url?scp=85123247761&partnerID=8YFLogxK
U2 - 10.3390/vaccines10010135
DO - 10.3390/vaccines10010135
M3 - Article
AN - SCOPUS:85123247761
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 1
M1 - 135
ER -